Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00392275 · ClinicalTrials.gov registry record · Phase 4

Penetrance of Third Generation Fluoroquinolones in Eyes With Functioning Filtering Blebs

A Phase 4 study of Cataract, sponsored by Indiana University School of Medicine.

Completed
Registry status
Phase 4
Development phase
48
Enrollment target
3
Study locations

NCT00392275 is a Phase 4 study of Cataract that has completed, run by Indiana University School of Medicine. The registered enrollment target is 48 participants, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (79% lower). The trial reports 3 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00392275, a Phase 4 study of Cataract, has completed, sponsored by Indiana University School of Medicine.

COMPLETED
Registry status
Phase 4
Development phase
48 participants
Enrollment target
3
Study locations

Study Summary

Based on previous results with eyes without filtering blebs, the aqueous concentrations of ofloxacin and levofloxacin will exceed the concentration of ciprofloxacin after either topical or topical plus oral administration.

Conditions Studied

Interventions

  • DRUG Ofloxacin 0.3%
  • DRUG Ciprofloxacin 0.3%
  • DRUG Levofloxacin 0.5%
  • DRUG Ofloxacin 400mg
  • DRUG Ciprofloxacin 400mg

Study Locations (3)

Indiana

  • Indiana University Hospital - Indianapolis
  • Richard L Rodeboush VA Medical Center - Indianapolis
  • Wishard Memorial Hospital - Indianapolis

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2002-11
Est. Completion 2006-05
Phase Phase 4

What the Registry Record Tells You About NCT00392275

The ClinicalTrials.gov registry entry for NCT00392275 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (79% lower). The listed sponsor is Indiana University School of Medicine, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cataract appearing as the primary indexed condition, and to 5 interventions - of which Ofloxacin 0.3% is the first listed.

NCT00392275 reports 3 study locations spanning 1 distinct geographic area - top geographies include Indiana.

Frequently Asked Questions

What is clinical trial NCT00392275 about?

NCT00392275 is a clinical study titled "Penetrance of Third Generation Fluoroquinolones in Eyes With Functioning Filtering Blebs". Based on previous results with eyes without filtering blebs, the aqueous concentrations of ofloxacin and levofloxacin will exceed the concentration of ciprofloxacin after either topical or topical plus oral administration.

What is the current status of trial NCT00392275?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 48 participants. The study started on 2002-11. Estimated completion is 2006-05.

What conditions does trial NCT00392275 study?

This clinical trial studies the following conditions: Cataract.

What interventions are being tested in trial NCT00392275?

The interventions under investigation include: Ofloxacin 0.3% (DRUG), Ciprofloxacin 0.3% (DRUG), Levofloxacin 0.5% (DRUG), Ofloxacin 400mg (DRUG), Ciprofloxacin 400mg (DRUG).

Who is sponsoring clinical trial NCT00392275?

This trial is sponsored by Indiana University School of Medicine, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00392275 being conducted?

This trial has 3 study locations across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cataract

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.